Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases

BACKGROUND: In the INBUILD trial in patients with chronic fibrosing interstitial lung diseases (ILDs) and a progressive phenotype, nintedanib reduced the rate of ILD progression with adverse events that were manageable for most patients. We investigated the potential impact of immunomodulatory thera...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Respir Res
Prif Awduron: Cottin, Vincent, Richeldi, Luca, Rosas, Ivan, Otaola, Maria, Song, Jin Woo, Tomassetti, Sara, Wijsenbeek, Marlies, Schmitz, Manuela, Coeck, Carl, Stowasser, Susanne, Schlenker-Herceg, Rozsa, Kolb, Martin
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2021
Pynciau:
Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7962343/
https://ncbi.nlm.nih.gov/pubmed/33726766
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-021-01668-1
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg